Depression drug enters pivotal studies as Peninsula company lands new CEO


If two of three 350-person studies hits their mark, the company plans in 2025 to ask the FDA to approve its drug.

Previous Stock Yards Bank continues to grow its reach in Greater Cincinnati
Next Kidney care provider DaVita adds to board of directors